Ionis Faces Its Easiest Earnings Comparison in Years With Expectations Already Reset

Ionis Pharmaceuticals (IONS) reports second-quarter 2026 earnings before the market opens on July 29, with analysts expecting a loss of $1.11 per share—a dramatic reversal from the $0.70 profit posted in the same quarter last year. The central question: can the biotech company stabilize its financial trajectory after a volatile year, or will deepening losses and deteriorating technical momentum push shares further below their 200-day moving average?

Part 1: Earnings Preview

Ionis Pharmaceuticals is a leading biotechnology company focused on discovering and developing RNA-targeted therapeutics for patients with serious diseases. The company's antisense technology platform enables it to create drugs that modulate RNA to treat conditions ranging from neurological disorders to cardiovascular disease.

For the quarter ending June 2026, analysts expect Ionis to report a loss of $1.11 per share on July 29 before the market opens. The most recently reported quarter (Q1 2026) delivered a loss of $0.56 per share, which beat estimates of -$0.89 by 37.08%. However, the upcoming quarter's consensus represents a stark year-over-year deterioration: last year's Q2 2025 produced a profit of $0.70 per share, making the current estimate reflect a -258.57% decline.

Three key themes define this earnings story:

Pipeline Progress and Regulatory Milestones: Investors will scrutinize updates on Ionis's late-stage clinical programs and any regulatory developments for its partnered drugs. The company's revenue model depends heavily on milestone payments and royalties from partners like AstraZeneca and Biogen, making pipeline advancement critical to near-term financial performance.

Partnership Economics and Licensing Activity: The dramatic swing from profitability to losses suggests variability in partnership revenue recognition. Analysts will focus on whether new licensing deals or milestone achievements can offset the absence of the large payments that drove last year's Q2 profit.

Operating Expense Management: With consensus estimates projecting continued losses through 2026 (full-year estimate of -$3.76 per share), cost discipline and R&D spending efficiency have become focal points. Investors want to see how management balances investment in the pipeline with the need to preserve cash runway.

Analyst commentary ahead of the release reflects caution about near-term profitability but maintains long-term conviction in the platform. The 22 analysts covering the stock have set a mean price target of $90.05, implying significant upside from current levels, though sentiment has deteriorated over the past month with two analysts downgrading from Strong Buy.

Part 2: Historical Earnings Performance

Ionis has demonstrated a pattern of volatile earnings performance with significant beats and misses over the past year. In Q2 2025, the company reported a profit of $0.70 per share against expectations of a -$0.11 loss—a massive 736.36% positive surprise that likely reflected substantial partnership milestone payments. The following quarter (Q3 2025) returned to losses with -$0.80 per share, though this still beat the -$1.23 estimate by 34.96%.

The trend turned negative in Q4 2025 when Ionis missed estimates, reporting -$1.41 per share versus the -$1.31 consensus for a -7.63% surprise. Most recently, Q1 2026 delivered another beat with -$0.56 per share against expectations of -$0.89, a 37.08% positive surprise. This pattern reveals a company whose quarterly results are heavily influenced by the timing of partnership payments and milestone achievements, making earnings difficult to predict with precision. The three beats in four quarters suggest management may be executing better than analysts model, though the magnitude of swings indicates continued volatility ahead.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Ionis typically reports earnings before the market opens, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price action shows moderate volatility around Ionis earnings releases, with an average absolute Day 0 move of 3.03% and Day +1 move of 2.05%. The most recent report (April 2026) produced a 4.25% gain on Day 0 followed by minimal movement on Day +1, consistent with a positive earnings surprise. However, the February 2026 report triggered a sharp -5.29% decline on Day 0, the largest recent move, reflecting disappointment despite a smaller-than-expected loss.

The pattern suggests initial reactions tend to be more pronounced than follow-through, with Day 0 ranges averaging 6.50% compared to 5.15% on Day +1. Investors should prepare for a potential swing of 3-5% in either direction based on whether results and guidance meet, beat, or miss expectations, with the direction heavily dependent on partnership revenue visibility and pipeline updates.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.36% expected move by the August 21 expiration, significantly higher than the historical average Day 0 move of 3.03%. This elevated implied volatility suggests options traders are anticipating a larger-than-typical reaction to this earnings release, possibly reflecting uncertainty around partnership revenue timing and the magnitude of the expected loss.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Ionis despite recent price weakness, with an average recommendation of 4.41 out of 5.00 (between Buy and Strong Buy). The consensus includes 14 Strong Buy ratings, 3 Moderate Buys, and 5 Holds, with no sell ratings among the 22 analysts covering the stock. The mean price target of $90.05 implies 63% upside from the current price of $55.30, with a range from $66.00 to $125.00.

However, sentiment has deteriorated over the past month, with the average recommendation slipping from 4.46 to 4.41 as two analysts downgraded from Strong Buy. The number of Strong Buy ratings declined from 16 to 14, suggesting some analysts are taking a more cautious near-term view even while maintaining overall positive ratings. This shift likely reflects concerns about the widening losses and uncertainty around the timing of partnership milestones that could return the company to profitability. Despite the recent downgrades, the substantial gap between the current price and analyst targets indicates the Street still sees significant value in Ionis's RNA-targeted therapeutics platform and partnership portfolio.

Part 4: Technical Picture

Ionis enters earnings in a deteriorating technical position, with the Barchart Technical Opinion showing a 100% Sell signal—a dramatic shift from the 8% Buy signal just one month ago. This represents one of the strongest and fastest technical reversals, indicating severe near-term momentum breakdown. The signal has remained at 100% Sell for the past week, confirming the weakness is not a brief fluctuation.

Timeframe Analysis:

• Short-term (100% Sell): Maximum sell signal indicates powerful near-term downward momentum heading into earnings
• Medium-term (100% Sell): Intermediate timeframe also shows maximum bearish pressure with no signs of stabilization
• Long-term (100% Sell): Even the longer-term trend has turned decisively negative, suggesting structural weakness beyond short-term volatility

Trend Characteristics: The signal strength is classified as Strong with Strongest directional conviction, indicating the technical deterioration is both powerful and unambiguous across all timeframes.

The stock is trading at $55.30, below all major moving averages: the 5-day ($55.54), 20-day ($63.81), 50-day ($70.68), 100-day ($72.47), and 200-day ($75.42). The only exception is the 10-day moving average ($54.78), which the stock has just barely crossed above. This positioning below longer-term averages confirms a sustained downtrend, with the stock having declined approximately 27% from its 200-day moving average.

The technical setup heading into earnings is decidedly cautionary. With the stock trapped below all significant moving averages except the 10-day, and the 20-day average at $63.81 representing the nearest resistance level, any positive earnings surprise would need to be substantial to trigger a meaningful technical reversal. The 50-day moving average at $70.68 represents an even more formidable overhead resistance zone. Conversely, if results disappoint, the lack of nearby support levels suggests vulnerability to further downside, particularly given the maximum sell signals across all timeframes. The technical damage is severe enough that even a modest earnings beat may struggle to generate sustained upside momentum without a significant shift in the fundamental narrative around partnership revenues and the path back to profitability.